Rxwire
In the news · 48h FDA 37 Eli Lilly 17 Roche 9 Merck & Co. (MSD) 7 Johnson & Johnson 4 AstraZeneca 3 Novo Nordisk 3 AbbVie 2
Approvals & regulatory · first seen yesterday, updated 4h ago

FDA adcomm votes in favor of benefit-risk of Grail’s cancer test

4 outlets FDA

An FDA advisory committee spent most of Wednesday raising questions about the utility and effectiveness of Grail’s multi-cancer test Galleri, but ultimately a majority of the panelists voted in favor of the test. The FDA's ...

Summary from Endpoints News.

Coverage 4 articles · 4 outlets

  1. Endpoints News
    FDA adcomm votes in favor of benefit-risk of Grail’s cancer test
  2. PR Newswire - FDA Approval
    FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
  3. pharmaphorum
    Grail cancer test gets lukewarm backing from FDA adcomm
  4. Targeted Oncology